Working in close partnership with RDSL’s more than 50 hospitals and more than 40 oncology clinics, where approximately 400 clinical oncologists and radio-oncologists work, IDOR’s oncology research team today has the necessary conditions to carry out large-scale studies with an impact on the world’s scientific literature. Therefore, in addition to leading projects conceived by its scientists, the oncology department at IDOR also participates in global studies, conducting clinical trials sponsored by pharmaceutical industries.

IDOR’s oncology research is concentrated in three main axes. The first is the epidemiological axis, which aims to understand how cancer appears in Brazil – a significant gap to fill in the literature, which has more abundant data on the epidemiology of the disease in other countries.

In the second axis – the molecular one – the researchers collect tissues to set up a tumor bank, generating data that could contribute to understanding predictive and prognostic factors of cancer. In addition, the knowledge acquired allows IDOR to increase its participation in research on new drugs development.

Finally, the therapy axis aims to develop new drugs to treat cancer patients, especially immunotherapies. IDOR has been taking part in studies focusing on a new generation of immunotherapies, while also seeking to deepen its knowledge in the field of cellular therapies as well.

The large volume of patients treated by RDSL and Oncologia D’Or, combined with the qualified medical staff prepared to support clinical trials, places the cancer research carried out by IDOR in a leading position in Latin America.